COSYLAB LABORATORIJ ZA KONTROLNE SISTEME DD

Their core work

Cosylab is a Slovenian SME specializing in control system software for particle accelerators and medical particle therapy facilities. They develop treatment control software for proton and heavy ion therapy centers, enabling real-time beam management, medical imaging integration, and quality assurance automation. Beyond medical applications, they contribute software and control systems expertise to large-scale research infrastructures in nuclear physics and antimatter research. More recently, they have expanded into distributed AI systems and photovoltaic energy optimization.

What they specialise in

How they've shifted over time

In their early H2020 period (2015–2018), Cosylab focused heavily on fundamental accelerator physics — antimatter experiments, ion beam therapy research, and nuclear transmutation — reflecting their roots as a control systems provider for large physics facilities. From 2018 onward, a clear shift toward clinical and industrial applications emerged: real-time adaptive particle therapy (RAPTOR), treatment control software commercialization (C-TCS), and distributed AI systems (DAIS). This trajectory shows a company moving from research infrastructure support toward product-oriented medical technology and AI-driven automation.

Cosylab is transitioning from a research infrastructure software provider into a medical technology company with growing AI capabilities, making them an increasingly relevant partner for health-tech and clinical translation projects.

How they like to work

Cosylab operates almost exclusively as a specialist partner within large consortia (7 of 9 projects as participant), contributing focused software and control systems expertise rather than leading research agendas. With 183 unique partners across 26 countries, they maintain a remarkably broad European network for an SME, suggesting they are a trusted, well-known provider in the accelerator and particle therapy community. Their single coordinator role (C-TCS, an SME Phase 1 feasibility study) signals ambition to lead commercially-focused projects while continuing to serve as a reliable technical contributor in large research collaborations.

Cosylab has collaborated with 183 unique partners across 26 countries, an exceptionally wide network for an SME — driven by participation in large-scale research infrastructure projects like ARIES and HITRIplus that involve dozens of European institutions. Their network spans major accelerator labs, universities, and medical centers across Europe.

What sets them apart

Cosylab occupies a rare niche: a private SME that builds production-grade control software for the world's most demanding scientific instruments — particle accelerators and therapy machines. Unlike academic partners who contribute research, Cosylab delivers industrial-quality software that must work in real clinical and experimental settings, bridging the gap between research prototypes and operational systems. Their combination of deep accelerator physics knowledge with software engineering discipline makes them an ideal partner for projects that need to move from lab to clinic or from prototype to product.

Highlights from their portfolio

• C-TCS
  Their only coordinator project — an SME Phase 1 feasibility study for a disruptive treatment control software product, signaling their commercial ambitions in particle therapy.
• RAPTOR
  Largest single EC contribution (EUR 239,957) and represents their most advanced medical application: real-time adaptive particle therapy with integrated imaging and automated quality assurance.
• DAIS
  Marks a strategic expansion beyond accelerators into distributed AI systems, trustable AI, and cross-domain interoperability — a significant diversification of their technical portfolio.